Publication date: Jul 12, 2023
Every year, more than 3 million people with TB remain undiagnosed and 1 million die. Better diagnostics are essential to reducing the enormous burden of TB worldwide. The Assessing Diagnostics At Point-of-care for Tuberculosis (ADAPT) study seeks to reduce the burden of TB worldwide by evaluating faster, simpler, and less expensive TB triage and diagnostic tests.
| Concepts | Keywords |
|---|---|
| Biomarker | Adapt |
| Faster | Assessing |
| Months | Based |
| Novel | Care |
| Tuberculosis | Diagnostic |
| Diagnostics | |
| Factor | |
| Point | |
| Positive | |
| Reduce | |
| Risk | |
| Screening | |
| Test | |
| Tests | |
| Tuberculosis |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Tuberculosis |
| pathway | KEGG | Tuberculosis |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | HIV infection |
| pathway | REACTOME | HIV Infection |
| drug | DRUGBANK | Etoperidone |
Original Article
(Visited 1 times, 1 visits today)